Many retrospective studies in colon and lung cancers have demonstrated poor clinical outcomes as a result of treatment with EGFR tyrosine kinase inhibitors in patients harbouring KRAS mutations [74,75,76,77,78]. The gene discussed is EGFR; the disease is lung carcinoma.